Presentation at March 11, 2013 Research and Discovery Sub-Committee Meeting

1. Aaron Miscenich, President
New Orleans BioInnovation Center,
Inc.
www.neworleansbio.com

3. • $48 million LEED Gold Facility
• Formed under 2002 Legislation
• Part of a statewide network
(Shreveport, Baton Rouge, New
Orleans)
• LSUHSC/Tulane Partnership, with
focus on all New Orleans-based
universities
• Funded by LA Department of
Economic Development & DoC/EDA

4. Mission Statement
The mission of the New Orleans
BioInnovation Center is to provide
support and guidance to companies
commercializing biotechnologies in the
Greater New Orleans Area by facilitating
communications and promoting
entrepreneurial thinking.

5. REGIONAL & COMMUNITY DESIGN
Canal Street Streetcar Line

6. TYPICAL LAB FLOOR PLAN

9. Key Ingredients
• Research/Technology
• Experienced
Management
• Capital

10. Areas of Research
Expertise
• Infectious Diseases
• Cardiovascular
Disease/Hypertension
• Cancer Research & Treatments
• Neurosciences
• Obesity & Diabetes

11. Areas of Research
Expertise
• Biomedical Engineering
• Chemical Engineering
• Vaccines
• Peptides
• Drug Delivery

12. Attract
Management Expertise
Management Expertise
• National Recognition
• University Turnover/Recruitment
• Capital Sources
• Expatriates
• Fine Print Factor

13. Capital Sources
• Grant Opportunities - SBIR/STTR
• Economic Incentives
• Angel Investor
• R&D
• Quality Jobs
• Tech Commercialization & Jobs

14. Capital Sources
• Partner Capital
• VC/Angel Capital

15. Capital Sources
Programming
Programming
• Partnerships
• Operations CEA
• BoR Grants
• Innovation Loan & Technical Assistance
• Delta Recovery Authority
• EDA (with GNO, Inc.

16. Programmin
g
• Inventor Interviews
(academic researchers, private entrepreneurs)
• Market Analyses
• Patent Searches
• Business Plan Creation

17. Programmin
g
• Financing Strategies
• Pitch Presentation Preparation
• SBIR/STTR Grant Application Support
• Economic Incentives

18. Programmin
g
• Seminars, Webinars, Workshops
• Identifying sources of capital
(SBIR/STTR grants, Angel, VC)
• Understanding Intellectual Property,
Patent Law Reform, Tax Credits
• Round-Table Discussions
• Networking Events/Conferences
• Perkin Mentors

19. Results
Total Technologies Actively Supported: 50
Entrepreneurs Interviewed: 71
SBIR/STTR Phase 0 Applications 8
SBIR/STTR Phase I/II Applications 15 (28)
5
SBIR/STTR Phase I Funded ~ $2.3
million
Equity-based funding $14 million

20. NuMe Health is developing evidence-based prebiotic products
designed to alter bacterial populations in the GI tract to prevent and
manage serious health conditions. NuMe's initial products and research
are focusing on pre-diabetes, diabetes and unhealthy body weight.
Innogenomics is a genomics solution provider focused on developing
and marketing next-generation genetic testing solutions for paternity
and forensic applications. InnoGenomics has secured a strong IP
position related to their platform technology and is currently in a
research and development phase to optimize a forensic DNA testing kit
that will facilitate the use of biological samples that are substantially
smaller and/or more degraded than the current industry standard to
analyze crime scene evidence.
MiniVax is currently developing therapeutic and preventative vaccines
for Pneumocystis carinii, a fungal pathogen that can cause severe, and
often fatal, lung infections especially in patients with HIV or other
conditions affecting the immune system. MiniVax was recently
awarded a $600,000 advanced technologies STTR research and
development grant by the NIH.
NanoFex has developed novel nanoparticle technology that provides an
affordable, effective method for remediating common, yet extremely
dangerous, pollutants in groundwater.

21. Bioceptive is a medical device startup built on a patent-pending
intrauterine device (IUD) inserter that minimizes complications
associated with currently used inserters and insertion techniques.
Bioceptive has recently taken on pre-seed funding through two
independent outside investment groups in order to fund further
prototype validation studies.
VoiceHIT is a web-based platform that uses predictive modeling and
3rd-party applications and devices to leverage the power of data to
prompt action, facilitate collaboration, and proactively manage health.
This creates a seamless platform that extends to 3rd-party applications
and mobile health devices, breaks down silos, and integrates data in
order to proactively prompt action by providers and patients alike. The
Better DayTM platform facilitates 100% patient focus, saving time and
improving care.
Wibi+Works is developing methods to improve the anti-inflammatory
properties of stem-cells for use in a variety of disease states, including
rheumatoid arthritis. The ability to create uniform cellular therapeutics
with predictable behavior is anticipated to significantly augment the
efficacy of mesenchymal stem-cell therapeutics addressing
inflammation-related disorders.
ReactWell is a next-generation oil company developing technology to
produce high-volume biomass-based crude oil and various other
valuable commodities. Our technology bridges proven geothermal
technology, aquaculture and biofuels. ReactWell transforms waste and
biomass into clean, sustainable, and cost-effective synthetic crude oil.

22. Technology Start-Up Success

23. Community
56 Employees
Start-Ups
Capital Companies
CRO
Consultants

24. Community
Law Firms
VC/Angels
Professional Services
Business Support Services

25. Business Partners

26. Challenges
• Continued Development of an
Entrepreneurial Culture
• Maintaining and Growing Current Research
Base
• Workforce / Experienced Management
• Retaining Incubator Graduates
• Capital

27. Near Term
Strategy
• Expand Reach into Business Community
• Increased National Coverage of Mission,
Clients, Partners
• Attract National/International Partners
• Expand Programming
• Form Advisory Committee
• Establish Graduation Facility

28. New Orleans BioInnovation Center,
Inc.
www.neworleansbio.com